en
Scientific article
French

Hémostase. Le point sur les nouveaux antithrombotiques

Other titleUpdate on new antithrombotic treatments
Published inRevue médicale suisse, vol. 6, no. 232, p. 109-112
Publication date2010
Abstract

Update on new antithrombotic treatments Antithrombotic treatments are frequently prescribed in different clinical situations. Classical anticoagulants have some disadvantages. New anticoagulants have emerged recently. Fondaparinux is now prescribed for both prophylaxis and treatment of venous thromboembolism. Two drugs are particularly interesting: rivaroxaban and dabigatran. Concerning the new antiplatelet agents, many molecules such as prasugrel, ticagrelor, cangrelor, SCH530348 or terutroban have appeared recently. They are directed either to the P2Y12 receptor or to other original targets. Studies have shown an increased bleeding risk for some of them as well as unexpected side effects. In the next future, these new molecules could allow a more individualised prescription of antithrombotic agents.

Keywords
  • Anticoagulants/*pharmacology
  • Clinical Trials as Topic
  • Humans
  • Platelet Aggregation Inhibitors/*pharmacology
  • Thrombosis/*prevention & control
Citation (ISO format)
BOEHLEN, Françoise et al. Hémostase. Le point sur les nouveaux antithrombotiques. In: Revue médicale suisse, 2010, vol. 6, n° 232, p. 109–112.
Identifiers
ISSN of the journal1660-9379
473views
0downloads

Technical informations

Creation05/22/2012 3:14:59 PM
First validation05/22/2012 3:14:59 PM
Update time03/14/2023 5:29:37 PM
Status update03/14/2023 5:29:37 PM
Last indexation01/15/2024 11:36:51 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack